Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Atea Pharmaceuticals, Inc. Director's Dealing 2020

Nov 4, 2020

33577_dirs_2020-11-03_e6a0b252-1300-402e-b119-87433d1b6af5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-11-03

Reporting Person: Chu Chung K. (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-11-03 Common Stock C 176862 Acquired 1176862 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-11-03 Series A Convertible Preferred Stock $ C 100000 Disposed Common Stock (100000) Direct
2020-11-03 Series B Convertible Preferred Stock $ C 33003 Disposed Common Stock (33003) Direct
2020-11-03 Series C Convertible Preferred Stock $ C 43859 Disposed Common Stock (43859) Direct

Footnotes

F1: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.